Abstract
Patients with early stage non small cell lung cancer (NSCLC) have historically been treated by resection alone, with results that have been superior to the results seen with radiation alone. This reflects the selection bias inherent to any comparison of operative and non-operative patients but surgery remains preferred treatment option. However, relapse rate after surgery is significant. In addition, a large proportion of these patients are not amenable to surgery due to medical co-morbidities and co-existing illnesses. These patients typically undergo a course of conventional radiotherapy, which provides poor outcomes both in terms of local control and survival. Attempts at dose escalation have met with some success, but local failures remain common and further dose escalation is limited by unacceptable toxicities. SRT allows for the delivery of a very high dose of radiation to a precise target. SRT presents the challenge of organ motion throughout the respiratory cycle. We review methods to mitigate this problem using both frame-based and frameless techniques, implanted fiducial markers, respiratory gating or deep inspiratory breath hold, and image guidance. Clinical experience with lung SRT continues to grow. Toxicities have been surprisingly mild. Based on available evidence, SRT appears to be effective, convenient and well tolerated.
Keywords: Lung cancer, radiosurgery, non small cell, body radiosurgery, extracranial radiosurgery
Current Cancer Therapy Reviews
Title: Emerging Role of Stereotactic Radiotherapy (SRT) in the Treatment of Early Stage Non-Small Cell Lung Cancer
Volume: 5 Issue: 4
Author(s): Joshua D. Lawson, Ajay Sandhu, Steve Jiang and Arno J. Mundt
Affiliation:
Keywords: Lung cancer, radiosurgery, non small cell, body radiosurgery, extracranial radiosurgery
Abstract: Patients with early stage non small cell lung cancer (NSCLC) have historically been treated by resection alone, with results that have been superior to the results seen with radiation alone. This reflects the selection bias inherent to any comparison of operative and non-operative patients but surgery remains preferred treatment option. However, relapse rate after surgery is significant. In addition, a large proportion of these patients are not amenable to surgery due to medical co-morbidities and co-existing illnesses. These patients typically undergo a course of conventional radiotherapy, which provides poor outcomes both in terms of local control and survival. Attempts at dose escalation have met with some success, but local failures remain common and further dose escalation is limited by unacceptable toxicities. SRT allows for the delivery of a very high dose of radiation to a precise target. SRT presents the challenge of organ motion throughout the respiratory cycle. We review methods to mitigate this problem using both frame-based and frameless techniques, implanted fiducial markers, respiratory gating or deep inspiratory breath hold, and image guidance. Clinical experience with lung SRT continues to grow. Toxicities have been surprisingly mild. Based on available evidence, SRT appears to be effective, convenient and well tolerated.
Export Options
About this article
Cite this article as:
Lawson D. Joshua, Sandhu Ajay, Jiang Steve and Mundt J. Arno, Emerging Role of Stereotactic Radiotherapy (SRT) in the Treatment of Early Stage Non-Small Cell Lung Cancer, Current Cancer Therapy Reviews 2009; 5 (4) . https://dx.doi.org/10.2174/157339409789712636
DOI https://dx.doi.org/10.2174/157339409789712636 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Electrochemical Nano-biosensors as Novel Approach for the Detection of Lung Cancer-related MicroRNAs
Current Molecular Medicine Fc-fusion Proteins in Therapy: An Updated View
Current Medicinal Chemistry Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Laccases in Pharmaceutical Chemistry: A Comprehensive Appraisal
Mini-Reviews in Organic Chemistry The Influence of Lipophilicity on the Classification of Antitumor Acridinones Evaluated by Principal Component Analysis
Current Pharmaceutical Analysis The J-shaped Association Between Alcohol Consumption and Breast Cancer: A Case-Control Study
Current Nutrition & Food Science An Overview on the Different Approaches to Obtain Luminescent Hydrotalcite Nanoparticles and Films
Current Physical Chemistry Histone Deacetylase Inhibitors in Psoriasis Therapy
Current Drug Targets - Inflammation & Allergy Development and Uses of Offline and Web-Searchable Metabolism Databases - The Case of Benzo[a]pyrene
Current Drug Metabolism Anti-Cancer Compounds Targeted to VDAC: Potential and Perspectives
Current Medicinal Chemistry Clinical Pharmacology of EGFR/Met Inhibitors in Non-Small Cell Lung Cancer
Current Drug Targets Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Can we Consider Zoledronic Acid a New Antitumor Agent? Recent Evidence in Clinical Setting
Current Cancer Drug Targets CXC Chemokines in Angiogenesis Relevant to Chronic Fibroproliferation
Current Drug Targets - Inflammation & Allergy Development and Challenges of the Discovery of HER2 Inhibitors
Mini-Reviews in Medicinal Chemistry Growth Factors as Therapeutics for Diabetic Neuropathy
Current Drug Targets Application of PET to the Diagnosis, Staging, and Treatment of Locally Advanced Non-small Cell Lung Cancer
Current Medical Imaging Conventional Anticancer Therapeutics and Telomere Maintenance Mechanisms
Current Pharmaceutical Design Using Nutrigenomics to Evaluate Apoptosis as a Preemptive Target in Cancer Prevention
Current Cancer Drug Targets Targeting Proteasomal Pathways by Dietary Curcumin for Cancer Prevention and Treatment
Current Medicinal Chemistry